Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?
- PMID: 28689694
- PMCID: PMC5643222
- DOI: 10.1016/j.urolonc.2017.06.042
Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?
Abstract
Objectives: To evaluate the influence of lamina propria invasion type at initial transurethral resection (TUR) on restaging pathology.
Materials and methods: We reviewed prospectively maintained records of all patients with a high-grade pT1 nonmuscle invasive bladder cancer who underwent both initial and restaging TUR within 6 weeks at our center between 2001 and 2016. The pathology of second TUR specimens was analyzed with regard to the characteristics of lamina propria invasion found at initial resection.
Results: We included 198 patients, with a median age of 70 years (interquartile range: 63-79). Muscle was present in the initial TUR specimen in 107 patients (54%). Pathology restaging was pT0 in 73 patients (37%), pTis in 44 (22%), pTa in 27 (14%), pT1 in 50 (25%), and pT2 in 4 (2%). Eighty-seven patients (44%) had tumors with minimal lamina propria invasion at initial TUR: 53 specimens (27%) had focal invasion (few malignant cells in the lamina propria); 15 specimens (7.6%) had superficial invasion (invasion of the lamina propria to the level of the muscularis mucosae [T1a]); and 19 specimens (10%) had multifocal superficial invasion (multiple areas of T1a). Of the patients with minimal lamina propria invasion, residual disease was found in 54 patients (62%). However, none of those patients had T2 disease.
Conclusions: A significant number of patients with T1 tumors have residual disease at restaging TUR as do patients with minimal lamina propria invasion. The extent of T1 invasion does not eliminate the need for repeat TUR.
Keywords: Bladder cancer; Diagnosis; Prognosis; Transurethral resection; Urothelial carcinoma.
Copyright © 2017 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest: none
Similar articles
-
Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature.J Endourol. 2008 Dec;22(12):2699-704. doi: 10.1089/end.2008.0281. J Endourol. 2008. PMID: 19025393 Review.
-
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272. Arch Ital Urol Androl. 2017. PMID: 29473376
-
Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22. Int J Urol. 2018. PMID: 29473226
-
Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.J Urol. 2021 Jun;205(6):1622-1628. doi: 10.1097/JU.0000000000001630. Epub 2021 Jan 27. J Urol. 2021. PMID: 33502235
-
Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.Adv Anat Pathol. 2017 May;24(3):113-127. doi: 10.1097/PAP.0000000000000152. Adv Anat Pathol. 2017. PMID: 28398951 Review.
Cited by
-
The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer.Transl Androl Urol. 2019 Feb;8(1):46-53. doi: 10.21037/tau.2018.10.19. Transl Androl Urol. 2019. PMID: 30976568 Free PMC article. Review.
-
The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.Int J Clin Oncol. 2020 Apr;25(4):698-704. doi: 10.1007/s10147-019-01581-0. Epub 2019 Nov 23. Int J Clin Oncol. 2020. PMID: 31760524 Clinical Trial.
-
Identification of potential prognostic factors for absence of residual disease in the second resection of T1 bladder cancer.Cent European J Urol. 2019;72(3):252-257. doi: 10.5173/ceju.2019.1908. Epub 2019 Sep 16. Cent European J Urol. 2019. PMID: 31720026 Free PMC article.
-
Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years' experience.Wideochir Inne Tech Maloinwazyjne. 2019 Apr;14(2):284-296. doi: 10.5114/wiitm.2018.79993. Epub 2018 Dec 19. Wideochir Inne Tech Maloinwazyjne. 2019. PMID: 31118996 Free PMC article.
-
Comparing Robotic-Assisted to Open Radical Cystectomy in the Management of Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched-Pair Analysis.Cancers (Basel). 2023 Sep 26;15(19):4732. doi: 10.3390/cancers15194732. Cancers (Basel). 2023. PMID: 37835425 Free PMC article.
References
-
- Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2016;69:60–9. doi: 10.1016/j.eururo.2015.06.045. - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical